Sun Pharma Will Take Concert’s Alopecia Drug The Rest Of The Way

 
• By Joseph Haas

Coming up after Lilly’s Olumiant and Pfizer’s ritlecitinib in alopecia areata, deuterated ruxolitinib is said to offer a differentiated profile including patient-reported outcomes data.

Concert in sun
Sun bids to buy Concert on the strenght of its alopecia candidate • Source: Shutterstock

More from Deals

More from Business